MedViz – a Research & Development cluster in Bergen. MedViz is a cluster of groups performing interdisciplinary research in advanced image analysis and visualisation bridging the gap between “bench and bedside”. MedViz also includes imaging physics and fundamental biomedical translational research. Our mission is to promote the development of biomedical and clinical imaging technologies with the ultimate goal of improving diagnosis and treatment of patients. MedViz wants to develop new clinical methods for potential commercialisation by means of denovo software for analysis, decision support and visual communication.
Invited talk 30.04.2013

Interactive Molecular Graphics: seeing and touching molecules in motion

we would like to invite you to the talk of Marc Baaden (Laboratoire de Biochimie Théorique, CNRS Paris) entitled
"Interactive Molecular Graphics: seeing and touching molecules in motion ". The talk will be held on Tuesday, April 30, and will take place from 10.00 to 11.0 at the Høyteknologisenteret, datablokk, in the Store auditorium at the second floor.
You can find more details in this link.
We hope to see you all!
with best regards, The Visualization Group
Last Updated on Tuesday, 23 April 2013 08:38
Quantitative molecular imaging in preclinical cancer research

Quantitative molecular imaging in preclinical cancer research

Dr. Ralf Bergmann from Institut für Radiopharmazie, Radiopharmazeutische Biologie, Helmholtz-Zentrum Dresden-Rossendorf will give a presentation at BBB, 3rd floor in Auditorium 4,  on Friday 19.04 at 12:15 (BBB is behind Sentralblokken, HUH)


Ralf Bergmann PhD

Helmholtz-Zentrum Dresden-Rossendorf

Institute of Radiopharmaceutical Cancer Research

The advances in preclinical cancer research, our understanding of the development of diseases at the molecular, cellular and tissue level have been supplemented by the ‘molecular imaging’, which provides for in vivo visualization of molecular, genetic and metabolic events in living organisms. Molecular imaging is a noninvasive assessment of gene and protein function, protein–protein interaction and/or signal transduction and metabolic pathways in animal models of human disease and in patients to provide insights into biochemistry and molecular pathogenesis. The major imaging techniques that are currently available to assess the structural and functional alterations in vivo in small animals are (1) radionuclide-based positron emission tomography (PET) and single photon emission computed tomography (SPECT), (2) X-ray-based computed tomography (CT), (3) magnetic resonance imaging (MRI) and spectroscopy (MRS), (4) optical luminescence and fluorescence imaging techniques and (5) ultrasound imaging (US). The functional imaging methods are using the indicator technology on tracer level. These methods require an imaging probe that is specific for a given molecular/cellular/tissue event. In preclinical imaging of small animal cancer models, the imaging probe could be an element of a direct or an indirect event. The primary events are often changes of the tissue perfusion and pathophysiologic, metabolic changes in the tumors. The perfusion, hypoxia and necrotic tumor heterogeneity determine the development and response to therapy of the tumors. The combination of morphologic and functional imaging is a key for quantitative characterization of the tumor models in preclinical imaging. The optical methods using intratumorally expressed luciferase or fluorescent proteins support this research field. The quantitative and parametric imaging of perfusion, metabolism and hypoxia is also the basis for more sophisticated approaches using multimodal probes. Small and large targeting cytostatic drug conjugates have a great potential in cancer treatment. Radiolabeled peptides and antibodies can be used as models of such drug conjugates and there pharmacokinetics and metabolism in tumor models will be discussed. The in vivo visualization of components of immunotherapy using bispecific antiPSCA-Ab’s will help to test this approach in animal models.

Quantitative preclinical imaging is a key to understanding of metabolism and targeting of new cancer diagnostic and treatment drugs.

Acknowledgment: The work was supported by EU Health Collaborative Project GIPIO Grant Agreement Number 223057, the BMBF project 02NUK006A “and the DFG project BE 2607/1-1, ZI 1362/2-1.

Last Updated on Monday, 15 April 2013 08:53
MedIm Bridging Grants

MedIm Bridging Grants

A reminder about this opportunity to "bridge" a talented student from completed studies and into a PhD posisition: 
MedIm (Norwegian Research School in Medical Imaging) will offer four grants, each of NOK 200.000, to recent master graduates or newly completed Medical Doctors, who are in need for salary funds for a shorter period while applying for a PhD grant. Our aim is to give talented students a chance to stay within the field of medical imaging, by providing continuity of income for about 4 months in the period between final exams and the initiation
of a PhD project.
The deadline for applications is 5 April 2013.
For additional information, please consult the full text announcement, at
Last Updated on Wednesday, 03 April 2013 12:59
More Articles...
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 14 of 39
GoogleNewsCheap Levitra Online